Skip to content

Contact +44 (0) 20 7060 7474 email us

Therapeutic

New Therapeutics and Diagnostics for Women’s Disorders

 

Publication Date May 2005
Publisher Business Communications Company
Product Type Report
Pages 211
ISBN Number not applicable
Product Code BCC00004

Price

£2,960.00
approximately: $4,852 | €3,452

print

Buy Now

Order above formats by FAX

Order by Fax

Summary

Women's disorders involve many different areas. The most obvious covered under this broad title are those dealing with reproduction, menstruation, cancer, pregnancy and menopause. However, these are far from the only ones. Several other disorders and diseases are especially prevalent in women such as rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, osteoporosis and others.

New therapeutics and diagnostics have emerged in the last few years that have had a significant impact on women's health. This covers a wide variety of products and disorders that predominantly affect women. Ongoing patient management studies will increase the number of indications. This BCC study provides the knowledge to adequately view and assess the women's health care movement and it will provide insights into market potentials. The report is the second update of a document last published in January 2001 and provides a thorough evaluation of the market for women's therapeutic and diagnostic products as it has changed in the years since.

Scope Of Study

The report contains:

  • Identification of the markets in general segments:
- autoimmune diseases - women's cancer - gynecological diseases and infections - kidney and urological diseases and infections - reproductive-related therapies and diagnostics - rheumatoid arthritis and osteoporosis
  • Detailed information based on product categories and their use
  • U.S. market forecasts through 2009
  • Competitive analyses and leading company profiles.

Report Highlights

  • The total U.S. market for new therapeutics and diagnostics for women's disorders was estimated at more than $25 billion in 2004 and is expected to reach nearly $41 billion in 2009, rising at an AAGR (average annual growth rate) of 10.3%.
  • Treatments for cancers specific to women will rise the fastest, at an AAGR of 12.6% and will lead revenues in 2009.
  • Reproductive-related therapies and diagnostics currently represent the largest market segment, but, rising at an AGR of 8.4%, will lag slightly by 2009.
  • Treatments for gynecological diseases and infections and for rheumatoid arthritis and osteoporosis also represent large market segments.

Contents

  • Introduction
    • Study Goals And Objectives
    • Reasons For Doing The Study
    • Scope And Format
    • Methodology
    • Related BCC Studies
    • Analyst Credentials
    • BCC Online Services
    • Disclaimer
  • Summary
    • Summary Table: U.S. Market For New Therapeutics And Diagnostics For Women's Disorders By Segment, Through 2009 ($ Million)
    • Summary Figure: U.S. Market For New Therapeutics And Diagnostics For Women's Disorders By Segment, 2002-2009 ($ Million)
  • Industry Overview
    • Definition Of Women's Disorders
    • Importance Of The Industry And Demographics
    • History Of The Industry And Response To Women's Healthcare Needs
    • Regulatory Environment
    • Effects Of Aging
    • Contraceptive Insurance Coverage
    • Contraceptive Use In Teens Increases
    • Legislative Actions
    • New Use For Contraceptives
    • Aging And Infertility
    • Contraceptive Patch Linked To Deaths
    • Sexual Dysfunction In Cancer
    • Infertility And Cancer
      • Chemotherapy
      • Radiation
      • Prevention Strategies
    • Marketing And Women
    • Counterfeit Pharmaceuticals
    • Generic Participation
    • International Issues
  • Autoimmune Diseases
    • U.S. Market
      • Overview
      • Market Size
      • Competitive Analysis
    • Market By Disease Type
      • Chronic Fatigue Syndrome
        • Incidence And Mortality
        • Market Size And Growth
      • Fibromyalgia
        • Incidence
        • Diagnostics
        • History Of Widespread Pain
        • Pain In 11 Of 18 Tender Point Sites On Digital Palpation
        • Market Size And Growth
        • Current Market Participants
      • Scleroderma
        • Incidence And Mortality
        • Diagnostics
        • Market Size And Growth
      • Sjogren's Syndrome
        • Incidence And Mortality
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Systemic Lupus Erythematosus
        • Incidence And Mortality
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
    • In Development
      • Prestara
      • Ampligen
      • Riquent
      • All U.S. Products In Development
  • Women's Cancers
    • U.S. Market
      • Overview
      • Market Size
      • Competitive Analysis
    • Market By Type Of Cancer
      • Breast Cancer
        • Incidence And Mortality
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Cervical Cancer
        • Incidence And Mortality
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Endometrial Cancer
        • Incidence And Mortality
        • Market Size And Growth
        • Current Market Participants
      • Ovarian Cancer
        • Incidence And Mortality
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
    • In Development
      • Abraxane
      • Mitoextra
      • 572016
      • Actimmune
      • Arzoxifene
      • Atamestane
      • Faslodex
      • Imc-C2259
      • Lasfoxifene
      • Ovarex
      • R1549
      • Temsirolimus
      • Theragyn
      • Theratope
      • Xyotax
      • All U.S. Products In Development
  • Gynecological Infections And Sexually Transmitted Diseases
    • U.S. Market
      • Overview
      • Market Size
      • Competitive Analysis
    • Market By Disease Type
      • Bacterial Vaginosis
        • Incidence
        • Market Size And Growth
        • Current Market Participants
      • Candidiasis
        • Incidence
        • Market Size And Growth
        • Current Market Participants
      • Cervical Dysplasia
        • Incidence
      • Chlamydia
        • Incidence
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Condyloma
        • Incidence
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Dysmenorrhea
        • Incidence
        • Market Size And Growth
        • Current Market Participants
      • Endometriosis
        • Incidence
        • Market Size And Growth
        • Current Market Participants
      • Fibroids
        • Incidence
        • Market Size And Growth
        • Current Market Participants
      • Genital Herpes
        • Incidence
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Pelvic Inflammatory Disease
        • Incidence
        • Market Size And Growth
        • Current Market Participants
    • In Development
      • Arcoxia
      • Clindesse
      • Endometrion
      • Human Papillomavirus
      • Low Dose Oral Interferon-Alpha
      • All U.S. Products In Development
  • Kidney And Urologic Diseases And Conditions
    • U.S. Market
      • Overview
      • Market Size
      • Competitive Analysis
    • Market By Infection Type
      • Urinary Tract Infections
        • Incidence
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
      • Urinary Incontinence
        • Incidence
        • Market Size And Growth
        • Current Market Participants
      • Urinary Interstitial Cystitis
        • Incidence
        • Market Size And Growth
        • Current Market Participants
    • In Development
      • Duloxetine
      • Enablex
      • Proquin Xr
      • Vesicare
      • Fesoterodine
      • All U.S. Products In Development
  • Reproductive-Related Therapeutics And Diagnostics
    • U.S. Market
      • Overview
      • Market Size
      • Competitive Analysis
    • Market By Type
      • Contraception
        • Market Size And Growth
        • Most Commonly Used Oral Contraceptives
        • Current Market Participants
      • Infertility
        • Incidence
        • Market Size And Growth
        • Hormonal Therapy
        • Surgical Treatment
        • Artificial Insemination
        • Assisted Reproductive Technology
        • Current Market Participants
      • Menopause
        • Incidence
        • Market Size And Growth
        • Most Commonly Used Menopause Treatment Products
        • Current Market Participants
    • In Development
      • Angeliq
      • Enjuvia
      • Femtrace
      • Luveris
      • Yasmin 20
      • Bazedoxifene/Conjugated Estrogens
      • C31g Vaginal Gel
      • Dvs-233
      • Evamist
      • Implanon
      • Librel
      • Mirena/Mls
      • All U.S. Products In Development
  • Rheumatoid Arthritis And Osteoporosis
    • U.S. Market
      • Overview
      • Market Size
      • Competitive Analysis
    • Market By Type
      • Rheumatoid Arthritis
        • Incidence And Mortality
        • Market Size And Growth
        • Aspirin And Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
        • Cox-2 Inhibitors
        • Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
        • Immunosuppressants
        • Corticosteroids
        • Tumor Necrosis Factor Blocker (TNF)
        • Current Market Participants
      • Osteoporosis
        • Diagnostics
        • Market Size And Growth
        • Current Market Participants
    • In Development
      • Arcoxia
      • Boniva
      • Fortical
      • Humira
      • Menostar
      • Prexige
      • Remicade
      • Preos
      • Arzoxifene
      • Lasofoxifene
      • Zometa
      • All U.S. Products In Development
  • Sexual Dysfunction
    • Overview
    • Incidence
    • Diagnostics
    • Market Analysis
    • In Development
      • Alista
      • Estratest
      • Intrinsa
      • All U.S. Products In Development
  • Market Summary
    • U.S. Women's Healthcare Market Analysis
  • Industry Participants By Type
    • Selected Company Profiles
      • Astrazeneca
      • Barr Laboratories, Inc.
      • Bristol-Myers Squibb Co.
      • Eli Lilly & Co.
      • Genentech
      • Glaxosmithkline
      • Merck & Co., Inc.
      • Ortho-Mcneil Pharmaceuticals
      • Pfizer
      • Serono International S.A.
      • Wyeth
    • List Of Companies
  • List Of Figures
    • Summary Table: U.S. Market For New Therapeutics And Diagnostics For Women's Disorders By Segment, Through 2009 ($ Million)
    • Table 1 U.S. Female Population By Age Group, Through 2020 (MILLIONS)
    • Table 2 U.S. Prescription Generic Drug Approvals By Company And Approval Date 2003-2004
    • Table 3 U.S. Market For Autoimmune Diseases By Product Segment, Through 2009 ($ Million)
    • Table 4 Manufacturers Of Autoimmune Disease Products, 2004
    • Table 5 Total Yearly Cases Of Chronic Fatigue Syndrome In Women In The U.S., 2004 And 2009
    • Table 6 Total Yearly Cases Of Fibromyalgia In Women In The U.S., Through 2009
    • Table 7 U.S. Fibromyalgia Market, Through 2009 ($ Million)
    • Table 8 Total Yearly Cases Of Scleroderma In Women In The U.S., Through 2009
    • Table 9 Total Yearly Cases Of Sjogren's Syndrome In Women In The U.S., Through 2009
    • Table 10 Sjogren's Syndrome U.S. Market, Through 2009 ($ Millions)
    • Table 11 Sjogren's Syndrome U.S. Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 12 Total Yearly Cases Of Systemic Lupus Erythematosus In Women In The U.S., Through 2009
    • Table 13 Systemic Lupus Erythematosus U.S. Market, Through 2009 ($ Million)
    • Table 14 Systemic Lupus Erythematosus U.S. Market By Competitor Revenue, 2004 ($ Millions, %)
    • Table 15 U.S. Autoimmune Disease Products In Development, 2004
    • Table 16 U.S. Market For Women's Cancer By Product Segment, Through 2009 ($ Million)
    • Table 17 U.S. Women's Cancer Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 18 Manufacturers Of Women's Cancer Products, 2004
    • Table 19 Tnm Classifications Of Breast Cancers
    • Table 20 5-Year Survival Rate Based On Stage Of Breast Cancer For Women In U.S, 2004 (%)
    • Table 21 Total Yearly Cases And Deaths For Breast Cancer In Women In The U.S., Through 2009
    • Table 22 U.S. Breast Cancer Market, Through 2009 ($ Million)
    • Table 23 U.S. Breast Cancer Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 24 Total Yearly Cases And Deaths For Cervical Cancer In Women In The U.S., Through 2009
    • Table 25 U.S. Cervical Cancer Market, Through 2009 ($ Million)
    • Table 26 U.S. Cervical Cancer Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 27 Total Yearly Cases And Deaths For Endometrial Cancer In Women In The U.S., Through 2009
    • Table 28 U.S. Endometrial Cancer Market, Through 2009 ($ Million)
    • Table 29 U.S. Endometrial Cancer Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 30 Total Yearly Cases And Deaths For Ovarian Cancer In Women In The U.S., Through 2009
    • Table 31 U.S. Ovarian Cancer Market, Through 2009 ($ Million)
    • Table 32 U.S. Ovarian Cancer Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 33 Women's Cancer Products In Development In The U.S., 2004
    • Table 34 U.S. Gynecological Diseases And Infections
    • Table 35 U.S. Market For Gynecological Diseases And Infections By Product Segment, Through 2009 ($ Million)
    • Table 36 U.S. Gynecological Diseases And Infections Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 37 Manufacturers Of Gynecological Disease And Infection Products, 2004
    • Table 38 Total Yearly Cases Of Bacterial Vaginosis In Women In The U.S., Through 2009
    • Table 39 U.S. Bacterial Vaginosis Market, Through 2009 ($ Million)
    • Table 40 Bacterial Vaginosis Market By Competitors Revenues, 2004 ($ Million, %)
    • Table 41 Total Yearly Cases Of Candidiasis In Women In The U.S., Through 2009
    • Table 42 U.S. Candidiasis Market, Through 2009 ($ Million)
    • Table 43 U.S. Candidiasis Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 44 Total Yearly Cases Of Cervical Dysplasia In Women In The U.S., Through 2009
    • Table 45 Total Yearly Cases Of Chlamydia In Women In The U.S., Through 2009
    • Table 46 U.S. Chlamydia Market, Through 2009 ($ Millions)
    • Table 47 U.S. Chlamydia Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 48 Total Yearly Cases Of Condyloma In Women In The U.S., Through 2009
    • Table 49 U.S. Condyloma Market, Through 2009 ($ Million)
    • Table 50 U.S. Condyloma Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 51 Total Yearly Cases Of Dysmenorrhea In Women In The U.S., Through 2009
    • Table 52 U.S. Dysmenorrhea Market, Through 2009 ($ Million)
    • Table 53 U.S. Dysmenorrhea Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 54 Total Yearly Cases Of Endometriosis In Women In The U.S., Through 2009
    • Table 55 U.S. Endometriosis Market, Through 2009 ($ Million)
    • Table 56 U.S. Endometriosis Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 57 Total Yearly Cases Of Fibroids In Women In The U.S., Through 2009
    • Table 58 U.S. Fibroids Market, Through 2009 ($ Million)
    • Table 59 U.S. Fibroids Market By Competitor Revenue, 2004 ($ Million)
    • Table 60 Total Yearly Cases Of Genital Herpes In Women In The U.S., Through 2009
    • Table 61 U.S. Genital Herpes Market, Through 2009 ($ Million)
    • Table 62 U.S. Genital Herpes Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 63 Total Yearly Cases Of Pelvic Inflammatory Disease In Women In The U.S., Through 2009
    • Table 64 Pelvic Inflammatory Disease Market, Through 2009 ($ Million)
    • Table 65 Pelvic Inflammatory Disease Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 66 Gynecological Disease And Infection Products In Development In The U.S., 2004
    • Table 67 U.S. Market For Kidney And Urological Diseases And Infections By Product Segment, Through 2009 ($ Million)
    • Table 68 U.S. Kidney And Urological Diseases And Infection Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 69 Manufacturers Of Kidney And Urologic Disease And Condition Products, 2004
    • Table 70 Total Yearly Cases Of Urinary Infections In Women In The U.S., Through 2009
    • Table 71 U.S. Urinary Infection Market, Through 2009 ($ Million)
    • Table 72 U.S. Urinary Infection Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 73 Total Yearly Cases Of Urinary Incontinence In Women In The U.S., Through 2009
    • Table 74 U.S. Urinary Incontinence Market, Through 2009 ($ Million)
    • Table 75 U.S. Urinary Incontinence Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 76 Total Yearly Cases Of Interstitial Cystitis In Women In The U.S., Through 2009
    • Table 77 U.S. Interstitial Cystitis Market, Through 2009 ($ Million)
    • Table 78 U.S. Interstitial Cystitis Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 79 Kidney And Urological Disease And Conditions Products In Development In The U.S., 2004
    • Table 80 U.S. Market For Reproductive-Related Therapeutics And Diagnostics By Product Segment, Through 2009 ($ Million)
    • Table 81 U.S. Reproductive-Related Therapeutics And Diagnostics Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 82 Contraceptive Use By Method For U.S. Women Age 15-44 By Race, 1995 (In Thousands)
    • Table 83 Most Commonly Used Oral Contraceptives In The U.S., 2004
    • Table 84 U.S. Contraception Market, Through 2009 ($ Million)
    • Table 85 U.S. Contraception Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 86 Total Yearly Cases Of Infertility In Women In The U.S., Through 2009
    • Table 87 U.S. Infertility Market, Through 2009 ($ Million)
    • Table 88 U.S. Infertility Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 89 Total Yearly Cases Of Menopause In Women In The U.S., Through 2009
    • Table 90 Most Commonly Used Menopause Treatment Products 2004
    • Table 91 U.S. Menopause Market, Through 2009 ($ Million)
    • Table 92 U.S. Menopause Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 93 Reproductive-Related Products In Development In The U.S., 2004
    • Table 94 U.S. Market For Rheumatoid Arthritis And Osteoporosis By Product Segment, Through 2009 ($ Million)
    • Table 95 U.S. Rheumatoid Arthritis And Osteoporosis Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 96 Manufacturers Of Rheumatoid Arthritis And Osteoporosis Products, 2004
    • Table 97 Total Yearly Cases Of Rheumatoid Arthritis In Women In The U.S., Through 2009
    • Table 98 U.S. Rheumatoid Arthritis Market, Through 2009 ($ Million)
    • Table 99 U.S. Rheumatoid Arthritis Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 100 Osteoporosis Incidence Rates For U.S. Women, 2004
    • Table 101 U.S. Osteoporosis Market, Through 2009 ($ Million)
    • Table 102 U.S. Osteoporosis Market By Competitor Revenue, 2004 ($ Million, %)
    • Table 103 Rheumatoid Arthritis And Osteoporosis Products In Development In The U.S., 2004
    • Table 104 Total Yearly Cases Of Sexual Dysfunction In Women In The U.S., Through 2009
    • Table 105 U.S. Sexual Dysfunction Market, Through 2009 ($ Million)
    • Table 106 U.S. Sexual Dysfunction Products In Development
    • Table 107 U.S. Women's Healthcare Market By Segment, Through 2009 ($ Million)
    • Table 108 Major Women's Healthcare Industry Participants By Product Type, 2004
  • List Of Figures
    • Summary Figure: U.S. Market For New Therapeutics And Diagnostics For Women's Disorders By Segment, 2002-2009 ($ Million)
    • Figure 1 U.S. Female Population By Age Group, 2000-2020 (MILLIONS)
    • Figure 2 U.S. Market For Autoimmune Diseases By Product Segment, 2002-2009 ($ Million)
    • Figure 3 U.S. Market For Women's Cancer By Product Segment, 2002-2009 ($ Million)
    • Figure 4 U.S. Market For Gynecological Diseases And Infections By Product Segment, 2002-2009 ($ Million)
    • Figure 5 U.S. Market For Kidney And Urological Diseases And Infections By Product Segment, 2002-2009 ($ Million)
    • Figure 6 U.S. Market For Reproductive-Related Therapeutics And Diagnostics By Product Segment, Through 2009 ($ Millions)
    • Figure 7 Contraceptive Use By Method For U.S. Women Age 15-44 By Race, 1995 (THOUSANDS)
    • Figure 8 U.S. Market For Rheumatoid Arthritis And Osteoporosis By Product Segment, 2002-2009 ($ Million)
    • Figure 9 U.S. Women's Healthcare Market By Segment, 2002-2009 ($ Million)